US 2006/0068442 A1 · Method for the identification of extracellular domains of Epstein Barr Virus (EBV) tumor-associated latent membrane proteins and for the selection of antibody reagents reactive therewith

Abstract

Described are a method for the identification of extracellular epitopes of Epstein Barr virus (EBV) encoded membrane proteins, expressed on the outer cell surface of EBV-transformed mammalian cells, methods fo rthe selection and preparation of antibody reagents specific for the said epitopes, as well as peptides, including extracellular domains of Epstein Barr Virus encoded tumour cell associated membrane proteins, the use of said peptide for immunization and therapeutic vaccination to induce antibodies and T-cells reactive with said domains, the use of said antibody reagents for the production of targeting cells, tumour cell purging and as diagnostic for and medicament against EBV-mediated malignant cell growth.

Claims25

Dependent claims

An isolated peptide, comprising an extracellular epitope of Epstein-Barr virus (EBV) encoded latent membrane proteins, characterized in that it is accessible on the outer cell surface of EBV-transformed mammalian cells for binding by antibody reagents, the peptide comprising one of the following:

SEQ ID 1 (LMP1, extracellular loop 1);
SEQ ID 2 (LMP1, extracellular loop 2);
SEQ ID 3 (LMP1, extracellular loop 3);
SEQ ID 4 (LMP2, extracellular loop 1);
SEQ ID 5 (LMP2, extracellular loop 2);
SEQ ID 6 (LMP2, extracellular loop 3);
SEQ ID 7 (LMP2, extracellular loop 4);
SEQ ID 8 (LMP2, extracellular loop 5);
SEQ ID 9 (LMP2, extracellular loop 6);
SEQ ID 10 (BARF1, SEQ 40-79);
SEQ ID 11 (BARF1, SEQ 80-154);
SEQ ID 12 (BARF1, SEQ 155-188);
or
SEQ ID 13 (BARF1, SEQ 188-221).

11 more elements

An isolated peptide, characterized in that it is accessible on the outer cell surface of EBV-transformed mammalian cells for binding by antibody reagents, the peptide having at least 80% amino acid sequence identity to:

(a) the amino acid sequence of SEQ ID 1 (LMP1, extracellular loop 1);
(b) the amino acid sequence of SEQ ID 2 (LMP1, extracellular loop 2);
(c) the amino acid sequence of SEQ ID 3 (LMP1, extracellular loop 3);
(d) the amino acid sequence of SEQ ID 4 (LMP2, extracellular loop 1);
(e) the amino acid sequence of SEQ ID 5 (LMP2, extracellular loop 2);
(f) the amino acid sequence of SEQ ID 6 (LMP2, extracellular loop 3);
(g) the amino acid sequence of SEQ ID 7 (LMP2, extracellular loop 4);
(h) the amino acid sequence of SEQ ID 8 (LMP2, extracellular loop 5);
(i) the amino acid sequence of SEQ ID 9 (LMP2, extracellular loop 6);
(j) the amino acid sequence of SEQ ID 10 (BARF1, SEQ 40-79);
(k) the amino acid sequence of SEQ ID 11 (BARF1, SEQ 80-154);
(l) the amino acid sequence of SEQ ID 12 (BARF1, SEQ 155-188);
or
(m) the amino acid sequence of SEQ ID 13 (BARF1, SEQ 188-221).

11 more elements

A method for identifying extracellular epitopes of Epstein Barr virus (EBV) encoded latent membrane proteins comprising the steps of:

A) providing the amino acid sequence of at least one open reading frame (ORF) of the EBV genome;
B) determining at least one putative extracellular domain contained within the amino acid sequence of (A);
C) preparing a peptide comprising the putative extracellular domain of (B) or a part thereof in a constrained forced circular form, the peptide not comprising the full-length ORF;
D) preparing an antibody reagent capable of specifically binding with the peptide of (C);
E) reacting the antibody reagent of (D) with viable EBV transformed mammalian cells;
and
F) detecting specific binding of the antibody reagent to the cell surface of the EBV transformed mammalian cells.

4 more elements

Dependencies are inferred from the claim text.

Method for the identification of extracellular domains of Epstein Barr Virus (EBV) tumor-associated latent membrane proteins and for the selection of antibody reagents reactive therewith

Life of this patent

Method for the identification of extracellular domains of Epstein Barr Virus (EBV) tumor-associated latent membrane proteins and for the selection of antibody reagents reactive therewith

Life of this patent

Abstract

Claims25